clinical trial · NCT04072458
A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies
Mantle Cell LymphomaPeripheral T-cell Lymphoma (PTCL)Cutaneous T-cell Lymphoma (CTCL)Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)Follicular LymphomaMarginal Zone LymphomaHodgkin LymphomaL-Bcl-2 antisense oligonucleotide
brief summary
This study evaluates the safety, pharmacokinetics, and efficacy of BP1002 (L-Bcl-2) antisense oligonucleotide in patients with advanced lymphoid malignancies. Up to 12 evaluable patients with a diagnosis of relapsed or refractory lymphoid malignancies are expected to participate.
started
Nov 5, 2020
primary completion
Apr 1, 2025
completion
Apr 1, 2025
last updated
Feb 24, 2025
official title
A Phase 1 Clinical Trial to Study the Safety, Pharmacokinetics, and Efficacy of BP1002 (L-Bcl-2) Antisense Oligonucleotide in Patients With Advanced Lymphoid Malignancies
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol